Stephen Willey
Stifel, Nicolaus & Company, Incorporated, Research Division

All right. Good afternoon, everyone. I'm Stephen Willey, one of the senior biotech analysts here at Stifel. And glad to have with us for the next session, Andrew Peters, who's the Senior Vice President of Strategy and IR at Exelixis. Andrew, thank you for the time. It's always appreciated.

Andrew Peters
Senior Vice President of Strategy

Yes. Glad to be here.

Stephen Willey
Stifel, Nicolaus & Company, Incorporated, Research Division

Maybe we can jump right into zanza, which obviously remains the focal point of an expanding development effort across a lot of different tumor types and lines of therapy. So you've got this December PDUFA date that's approaching in third-line colorectal based on the STELLAR-303 data. Just how do you think about the value proposition of this regimen in this setting? And do you think that there's a subset of later-line patients for whom this regimen might be best suited?

Andrew Peters
Senior Vice President of Strategy

Yes. Steve, glad to be here. Just as a reminder, I'll be making forward-looking statements today. So everyone online, please see our disclosures around risks to our business and our regulatory filings.

So it's an interesting place to start, and I'm glad you started kind of the discussion on zanza that way. Highlighting the breadth of what we're doing with zanza is really how we think about the business. Mike talked about it on the last earnings call, and we certainly highlighted at R&D Day, kind of this idea of franchises is really what we're trying to do, the